Welcome to our dedicated page for Resmed SEC filings (Ticker: RMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The ResMed Inc. (RMD) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures as filed with the U.S. Securities and Exchange Commission. ResMed’s common stock is registered under Section 12(b) of the Exchange Act and trades on the New York Stock Exchange under the symbol RMD, and its filings offer detailed insight into governance, compensation, capital returns, and financial performance.
Among the key documents available are Form 8-K current reports, where ResMed discloses material events. Recent 8-K filings describe quarterly and annual results of operations, dividend declarations, and changes in the composition of the board of directors. They also cover amendments to equity-based incentive plans and the employee stock purchase plan, including increases in reserved shares and changes to plan terms approved by stockholders at the annual meeting.
Investors can also review the company’s Definitive Proxy Statement on Schedule 14A, which discusses board structure, director elections, executive compensation, and long-term strategic priorities. The proxy materials outline ResMed’s mission around sleep and breathing health, its 2030 goals, and its approach to aligning incentive programs with performance and shareholder interests.
On Stock Titan, these filings are complemented by AI-powered summaries that help explain complex sections, such as compensation plans, dividend announcements, and voting results from the annual meeting. Users can quickly see what the board has approved, how stockholders voted on proposals, and how ResMed’s capital management policies, including recurring cash dividends, are documented in its official records.
Because Form 8-K reports and proxy statements are updated over time, the filings page offers a chronological view of ResMed’s regulatory history, from financial disclosures to governance changes. This makes it a useful resource for investors who want to understand how the company reports its performance, manages equity plans, and communicates significant events through the SEC’s EDGAR system.
ResMed Inc. (RMD) – Form 144 filing: Insider Michael Rider has notified the SEC of his intent to sell up to 50 common shares through Fidelity Brokerage on or about 01 Aug 2025 on the NYSE. The shares carry an estimated market value of $14,095 and originate from restricted-stock vesting on 11 Nov 2021 that was received as compensation.
The filing also discloses earlier open-market sales by Rider in the last three months: 41 shares on 02 Jun 2025 for $9,994.98 and 66 shares on 01 Jul 2025 for $16,961.34. In total, Rider has sold or proposes to sell 157 shares in the period, compared with the company’s 146,627,399 shares outstanding, resulting in a de-minimis ownership impact (<0.001%). No other material terms, lock-ups, or 10b5-1 plan details are provided in the notice.
ResMed Inc. (RMD) – Form 4 insider transaction: Director and Chairman emeritus Peter C. Farrell disclosed the sale of 945 common shares on 07/02/2025 at an average price of $255.49 per share. The trade, executed under a previously adopted Rule 10b5-1 trading plan dated May 28 2024, reduced Farrell’s direct holdings to 68,273 shares. No derivative securities were involved, and no additional transactions were reported.
The disposition represents roughly 1.4% of the insider’s pre-transaction stake and does not change his board status. Because the sale was pre-planned, it typically signals liquidity management rather than an active valuation call.
Form 4 Overview – ResMed Inc. (RMD)
Chief Financial Officer Brett Sandercock reported a series of option exercises and an open-market sale on 1 July 2025 under a pre-arranged Rule 10b5-1 trading plan dated 19 Feb 2025.
- Options exercised: 2,883 options (strike $101.64) converted into common shares. These options were granted 11 Nov 2019 and expire 14 Nov 2025.
- Shares sold: 3,883 common shares disposed at an average price of $256.99, generating gross proceeds of roughly $1.0 million.
- Net ownership change: Holding declined from 87,249 to 84,283 shares, a reduction of 2,966 shares (≈3.4% of his previously reported direct stake).
- Remaining equity exposure: Sandercock still owns 84,283 common shares and 8,000 vested, unexercised options, maintaining significant alignment with shareholders.
The transaction appears routine—driven by option maturity and executed under a 10b5-1 plan—but the net sale may be interpreted as mildly bearish sentiment or personal liquidity management. The limited magnitude relative to total holdings lessens market impact, yet investors often track C-suite sales as potential leading indicators.